Asthma: NICE recommends LTRA tablets over combination inhaler

  • NICE

  • from Pavankumar Kamat
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The new NICE draft guideline on asthma management currently under consultation recommends leukotriene receptor antagonist (LTRA) tablets over combination inhaler therapy in a move to boost savings for the NHS.

Key highlights

  • Newly diagnosed patients with asthma should be offered a short-acting beta2 agonist (SABA) to relieve symptoms as and when they occur.
  • A low-dose inhaled corticosteroid (ICS) is suitable as maintenance therapy for patients with symptoms uncontrolled by SABA.
  • If symptoms remain uncontrolled with ICS, patients should be offered an LTRA along with ICS before considering the combination (LABA + ICS) inhaler therapy.
  • If LTRAs fail to work, adult and young patients can be switched to a combination inhaler. Children, however, should be referred to a specialist in such a scenario. 
  • NICE recommends initiating treatment with the 7 pence a day LTRA tablet earlier than the current practice. This could translate to a saving £3 million a year for the NHS.
  • The clinical efficacy of both LTRAs and combination inhalers are strongly backed by evidence; however, the cost-effectiveness of LTRAs make them the primary choice.